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Children suffering from systemic onset juvenile idio-
pathic arthritis (soJIA) are often receiving high doses of
corticosteroids (CS) for a long time duration and there-
fore are suffering from many CS associated side effects.
The therapy of soJIA includes non steroidal antiinflam-
matory drugs, CS and methotrexate +/- azathioprine.
Other drugs like cyclosporin A, thalidomide and biologi-
cals like tumor necrosis factor alpha-inhibitors or -anti-
bodies have not been very successfully applied in many
children. During the last years the interleukin-1 receptor
antagonist anakinra and antibodies against interleukin
1ß have been developed and clinical experiences are
showing promising antiinflammatory activity.
We present six patients with soJIA. The age at diagno-
sis was 2, 2, 3, 5, 10 and 15 years. During kineret ther-
apy CS could be finished in five of them and is given in
a very low dosage of 5 mg prednisolone daily in the
sixth patient. The dose of kineret had to be individua-
lized. In 5 patients the dose of kineret varied between
1,3 mg/kg and 4 mg/kg per day. Sometimes it had to be
applied in two daily doses. In five patients kineret has
been applied for 5, 8, 24, 29 and 45 months. In the sixth
patient kineret has been applied for 15 months, and
then the ILß antibody canakinumab has been applied
for another 11 months in monthly intervals.
In May 2011 5/6 patients do not need any CS for
4,9,29,35 and 45 months, respectively. The sixth patient
suffering from a very severe chronic inflammatory dis-
ease is receiving low doses of 5 mg prednisolone per
day. Three of six patients are receiving additional low
doses of weekly methotrexate, three patients do not
need any immunosuppressive therapy at all.
Therapeutic drugs acting against interleukin 1 are pro-
mising therapeutic alternatives for patients suffering
from soJIA. The subcutaneous applicability is another
advantage. The duration of CS dependence may be
reduced in many patients suffering from soJIA.
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